GE HealthCare is a buy at $64.18, trading at a steep discount to peers (19.5x P/E vs. 25.4x median) despite steady mid-single-digit revenue growth and expanding margins. The recent wave of insider buying—including $5M by director Culp and open-market purchases by the CEO and CFO near $60—signals strong internal conviction that the sell-off is overdone. With a 14.1 P/E on 2025 estimates and a clean balance sheet, the risk/reward is compelling for a durable med-tech franchise.
Securities Fraud Investigation
Multiple law firms are investigating potential federal securities law violations following an April 29, 2026 report, creating headline and legal overhang that could further pressure the stock.
Technical Weakness
The stock trades below both its 50-day ($67.79) and 200-day ($75.48) moving averages with a neutral RSI of 47.4, indicating a persistent downtrend that may attract momentum sellers.
Free Cash Flow Compression
Free cash flow declined from $1.71B in 2023 to $1.51B in 2025, driven by rising capex (+24% YoY to $482M), which could limit capital return or reinvestment capacity.
Leverage Creep
Total debt has risen to $10.0B in 2025 from $8.6B in 2022, pushing the debt-to-equity ratio near 1.0x, which reduces balance-sheet flexibility if rates stay elevated.